IMMUNOLOGIC PREDICTORS 
OF RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS OF A PHASE IV PROSPECTIVE INTERVENTIONAL TRIAL